FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324133721> ?p ?o ?g. }

• W4324133721 endingPage "3121" @default.
• W4324133721 startingPage "3116" @default.
• W4324133721 abstract "Five-year data of the phase III trial TAM-01 showed that low-dose tamoxifen at 5 mg once daily administered for 3 years in women with intraepithelial neoplasia (IEN) reduced by 52% the recurrence of invasive breast cancer or ductal carcinoma in situ (DCIS), without additional adverse events over placebo. Here, we present the 10-year results.We randomly assigned 500 women with breast IEN (atypical ductal hyperplasia, lobular carcinoma in situ [LCIS], or hormone-sensitive or unknown DCIS) to low-dose tamoxifen or placebo after surgery with or without irradiation. The primary end point was the incidence of invasive breast cancer or DCIS.The TAM-01 population included 500 women (20% atypical ductal hyperplasia, 11% LCIS, and 69% DCIS). The mean (±SD) age at the start of treatment was 54 ± 9 years, and 58% of participants were postmenopausal. After a median follow-up of 9.7 years (IQR, 8.3-10.9 years), 66 breast cancers (15 in situ; 51 invasive) were diagnosed: 25 in the tamoxifen group and 41 in the placebo group (annual rate per 1,000 person-years, 11.3 with tamoxifen v 19.5 with placebo; hazard ratio [HR], 0.58; 95% CI, 0.35 to 0.95; log-rank P = .03). Most recurrences were invasive (77%) and ipsilateral (59%). Regarding contralateral breast cancer incidence, there were six events in the tamoxifen arm and 16 in the placebo arm (HR, 0.36; 95% CI, 0.14 to 0.92; P = .025). The number needed to be treated to prevent one case of breast event with tamoxifen therapy was 22 in 5 years and 14 in 10 years. The benefit was seen across all patient subgroups. There was a significant 50% reduction of recurrence with tamoxifen in the DCIS cohort, which represents 70% of the overall population (HR, 0.50; 95% CI, 0.28 to 0.91; P = .02). No between-group difference in the incidence of serious adverse events was reported during the prolonged follow-up period.Tamoxifen 5 mg once daily for 3 years significantly prevents recurrence from noninvasive breast cancer after 7 years from treatment cessation without long-term adverse events." @default.
• W4324133721 created "2023-03-15" @default.
• W4324133721 creator A5004984896 @default.
• W4324133721 creator A5011702331 @default.
• W4324133721 creator A5011883364 @default.
• W4324133721 creator A5012798471 @default.
• W4324133721 creator A5019084193 @default.
• W4324133721 creator A5022371820 @default.
• W4324133721 creator A5025357967 @default.
• W4324133721 creator A5025625557 @default.
• W4324133721 creator A5035211291 @default.
• W4324133721 creator A5044655947 @default.
• W4324133721 creator A5049232758 @default.
• W4324133721 creator A5055422607 @default.
• W4324133721 creator A5058796036 @default.
• W4324133721 creator A5062291346 @default.
• W4324133721 creator A5062416354 @default.
• W4324133721 creator A5075772633 @default.
• W4324133721 creator A5079114893 @default.
• W4324133721 creator A5080826945 @default.
• W4324133721 creator A5082783307 @default.
• W4324133721 creator A5084916075 @default.
• W4324133721 creator A5090199141 @default.
• W4324133721 creator A5090671983 @default.
• W4324133721 creator A5090914459 @default.
• W4324133721 date "2023-06-10" @default.
• W4324133721 modified "2023-10-16" @default.
• W4324133721 title "Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study" @default.
• W4324133721 cites W2011246022 @default.
• W4324133721 cites W2141647078 @default.
• W4324133721 cites W2157663195 @default.
• W4324133721 cites W2470726713 @default.
• W4324133721 cites W2619605504 @default.
• W4324133721 cites W2938233323 @default.
• W4324133721 cites W2971583637 @default.
• W4324133721 cites W2971696111 @default.
• W4324133721 cites W2972132614 @default.
• W4324133721 cites W3009442691 @default.
• W4324133721 cites W3038460242 @default.
• W4324133721 cites W3119812078 @default.
• W4324133721 cites W3129856913 @default.
• W4324133721 cites W3138246439 @default.
• W4324133721 cites W4226097827 @default.
• W4324133721 cites W4281747266 @default.
• W4324133721 doi "https://doi.org/10.1200/jco.22.02900" @default.
• W4324133721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36917758" @default.
• W4324133721 hasPublicationYear "2023" @default.
• W4324133721 type Work @default.
• W4324133721 citedByCount "7" @default.
• W4324133721 countsByYear W43241337212023 @default.
• W4324133721 crossrefType "journal-article" @default.
• W4324133721 hasAuthorship W4324133721A5004984896 @default.
• W4324133721 hasAuthorship W4324133721A5011702331 @default.
• W4324133721 hasAuthorship W4324133721A5011883364 @default.
• W4324133721 hasAuthorship W4324133721A5012798471 @default.
• W4324133721 hasAuthorship W4324133721A5019084193 @default.
• W4324133721 hasAuthorship W4324133721A5022371820 @default.
• W4324133721 hasAuthorship W4324133721A5025357967 @default.
• W4324133721 hasAuthorship W4324133721A5025625557 @default.
• W4324133721 hasAuthorship W4324133721A5035211291 @default.
• W4324133721 hasAuthorship W4324133721A5044655947 @default.
• W4324133721 hasAuthorship W4324133721A5049232758 @default.
• W4324133721 hasAuthorship W4324133721A5055422607 @default.
• W4324133721 hasAuthorship W4324133721A5058796036 @default.
• W4324133721 hasAuthorship W4324133721A5062291346 @default.
• W4324133721 hasAuthorship W4324133721A5062416354 @default.
• W4324133721 hasAuthorship W4324133721A5075772633 @default.
• W4324133721 hasAuthorship W4324133721A5079114893 @default.
• W4324133721 hasAuthorship W4324133721A5080826945 @default.
• W4324133721 hasAuthorship W4324133721A5082783307 @default.
• W4324133721 hasAuthorship W4324133721A5084916075 @default.
• W4324133721 hasAuthorship W4324133721A5090199141 @default.
• W4324133721 hasAuthorship W4324133721A5090671983 @default.
• W4324133721 hasAuthorship W4324133721A5090914459 @default.
• W4324133721 hasConcept C121608353 @default.
• W4324133721 hasConcept C126322002 @default.
• W4324133721 hasConcept C126894567 @default.
• W4324133721 hasConcept C142724271 @default.
• W4324133721 hasConcept C143998085 @default.
• W4324133721 hasConcept C204787440 @default.
• W4324133721 hasConcept C207103383 @default.
• W4324133721 hasConcept C27081682 @default.
• W4324133721 hasConcept C2777176818 @default.
• W4324133721 hasConcept C2780862961 @default.
• W4324133721 hasConcept C2908647359 @default.
• W4324133721 hasConcept C29456083 @default.
• W4324133721 hasConcept C44249647 @default.
• W4324133721 hasConcept C530470458 @default.
• W4324133721 hasConcept C71924100 @default.
• W4324133721 hasConcept C99454951 @default.
• W4324133721 hasConceptScore W4324133721C121608353 @default.
• W4324133721 hasConceptScore W4324133721C126322002 @default.
• W4324133721 hasConceptScore W4324133721C126894567 @default.
• W4324133721 hasConceptScore W4324133721C142724271 @default.
• W4324133721 hasConceptScore W4324133721C143998085 @default.
• W4324133721 hasConceptScore W4324133721C204787440 @default.
• W4324133721 hasConceptScore W4324133721C207103383 @default.
• W4324133721 hasConceptScore W4324133721C27081682 @default.

• next